Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
Nature|February 4, 2016
Backbone NMR reveals allosteric signal transduction networks in the β1-adrenergic receptorShin Isogai, Xavier Deupi, Christian Opitz, et al.Lung|September 14, 2015
MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PHMartin Kolditz, Hans-Jürgen Seyfarth, Heinrike Wilkens, et al.Journal of Cardiovascular Development and Disease|October 26, 2022
Prognostic Relevance of Cardiopulmonary Exercise Testing for Patients with Chronic Thromboembolic Pulmonary HypertensionRalf Ewert, Till Ittermann, Delia Schmitt, et al.European Heart Journal|August 2, 2015
Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trialNicola Ehlken, Mona Lichtblau, Hans Klose, et al.Pneumologie (Stuttgart, Germany)|October 6, 2025
[Pulmonary Hypertension Associated with Lung Diseases]Athiththan Yogeswaran, Dirk Skowasch, Vasile Foris, et al.Circulation|September 20, 2006
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertensionDerliz Mereles, Nicola Ehlken, Sandra Kreuscher, et al.Pneumologie (Stuttgart, Germany)|October 6, 2025
[Pulmonary Hypertension Associated with Left Heart Disease]Kai Helge Schmidt, Joana Adler, Olympia Bikou, et al.The European Respiratory Journal|February 11, 2012
Safety and efficacy of exercise training in various forms of pulmonary hypertensionEkkehard Grünig, Mona Lichtblau, Nicola Ehlken, et al.Circulation|June 28, 2024
Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.Pulmonary Circulation|May 4, 2022
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertensionMarc A Simon, Kate Hanrott, David C Budd, et al.Pageof 6